Accuray, Inc.

As of July 8, 2025, Accuray, Inc. is in a mildly bearish trend, with mixed technical indicators and underperformance compared to the S&P 500, showing a year-to-date return of -12.12% versus the S&P's 12.22%.

As of August 13, 2025, Accuray, Inc. is considered a risky investment due to its overvaluation, indicated by a high Price to Book Value of 2.68, an EV to EBITDA of 14.26, a low ROCE of 6.87%, a negative ROE of -0.73%, and underperformance against the S&P 500 with a year-to-date return of -12.12%.

As of June 10, 2025, Accuray, Inc. is considered overvalued with a valuation grade shift from attractive to expensive, highlighted by a high EV to EBITDA ratio of 14.26 compared to peers, a Price to Book Value of 2.68, and a year-to-date stock return of -36.87%.

As of June 5, 2025, Accuray, Inc. is in a strong bearish trend, supported by bearish MACD, moving averages, and KST indicators across both weekly and monthly timeframes.

As of March 2022, Accuray, Inc.'s management team includes CEO Joshua Levine and Independent Chairperson Louis Lavigne, along with several independent directors: Elizabeth Davila, James Hindman, Beverly Huss, Anne Le Grand, and Richard Pettingill.

Accuray, Inc. is a micro-cap radiation oncology company that develops and markets medical devices for cancer treatment, with recent net sales of $113 million and a market cap of $126.71 million. As of March 2025, the company reported a net profit of -$1 million and has a debt-to-equity ratio of 2.06.

As of Jun 24, Accuray, Inc. has a market capitalization of 126.71 million, with net sales of 465.25 million and a net profit of 0.68 million over the latest four quarters. Shareholder's funds are 45.08 million, and total assets are 468.63 million.